Compare STTK & APOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | APOG |
|---|---|---|
| Founded | 2016 | 1949 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.8M | 810.1M |
| IPO Year | 2020 | 1994 |
| Metric | STTK | APOG |
|---|---|---|
| Price | $7.30 | $42.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $10.00 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 1.3M | 157.8K |
| Earning Date | 05-01-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 3.03% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | $1,000,000.00 | ★ $1,404,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.07 |
| P/E Ratio | ★ N/A | $79.57 |
| Revenue Growth | N/A | ★ 3.21 |
| 52 Week Low | $0.80 | $30.75 |
| 52 Week High | $8.33 | $50.88 |
| Indicator | STTK | APOG |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 55.73 |
| Support Level | $5.87 | $37.04 |
| Resistance Level | $7.75 | $43.36 |
| Average True Range (ATR) | 0.52 | 1.24 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 55.08 | 69.80 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.